← Back to all protocols
24

Atrial Fibrillation with Rapid Ventricular ResponseCardiac

1 · Quick ED Algorithm

AF detected
↓
Assess ABCDE + haemodynamic stability
↓
Unstable (shock, acute pulmonary oedema, ongoing ischaemia, severe hypotension, altered mental status)? → Yes → immediate synchronised electrical cardioversion
↓
Not unstable → identify and treat any precipitating cause
↓
Assess ventricular rate and symptoms → choose rate control vs rhythm control
↓
Assess stroke risk: CHA₂DS₂-VASc / CHA₂DS₂-VA → anticoagulation decision
↓
Determine cardioversion requirements (AF duration, anticoagulation status)
↓
Discharge vs admission
↓
Arrange follow-up ± echocardiogram / cardiology referral

2 · Initial Assessment & AF Classification

  • Atrial fibrillation (AF): a supraventricular tachyarrhythmia with uncoordinated atrial activation and ineffective atrial contraction, producing an irregularly irregular ventricular rhythm
  • Rapid ventricular response (RVR): AF with a ventricular rate generally >100–110 bpm — this is a clinical description rather than one fixed cut-off; symptoms and haemodynamic status matter more than the exact rate
  • AF classification: new-onset/first diagnosed (first presentation, regardless of duration or symptoms) · paroxysmal (self-terminating, usually within 48 hours, up to 7 days) · persistent (continuous, lasting >7 days, or requiring cardioversion to terminate) · long-standing persistent (continuous for ≥1 year when a rhythm-control strategy is being pursued) · permanent (AF accepted by patient and clinician, with no further rhythm-control attempts planned)
  • Symptoms: palpitations; dyspnoea; chest pain; dizziness; syncope/presyncope; fatigue; exercise intolerance; symptoms of heart failure; symptoms of stroke/TIA
  • Look for a precipitating/reversible cause: sepsis/infection; hypovolaemia; electrolyte abnormalities; thyrotoxicosis; acute coronary syndrome; pulmonary embolism; hypoxia; alcohol; stimulants/recreational drugs; the post-operative state; heart failure; valvular heart disease; other acute illness

3 · Red Flags / Unstable Patient

  • Haemodynamic instability — look for: hypotension/shock; acute pulmonary oedema; severe acute heart failure; ongoing myocardial ischaemia; altered mental status; severe ongoing chest pain; other evidence of cardiovascular compromise
  • Any of the above → immediate synchronised electrical cardioversion — do not wait to see if rate-control drugs work first
  • Synchronised cardioversion approach: sedate/anaesthetise appropriately (e.g. procedural sedation or general anaesthesia per local practice) with full monitoring and resuscitation equipment available; confirm the defibrillator is set to synchronised mode — an unsynchronised shock risks inducing ventricular fibrillation
  • Initial energy: typically 120–150 J biphasic, stepping up (e.g. to 200 J) if the first shock is unsuccessful — follow your specific defibrillator's guidance, as recommended energies vary slightly between manufacturers
  • Sedation: short-acting agents (e.g. propofol ± an opioid) are commonly used; involve anaesthetics/senior ED support per local sedation policy
  • Anticoagulation: do NOT delay emergency cardioversion in an unstable patient to arrange anticoagulation first — give anticoagulation as soon as feasible (before or immediately after) and continue it afterwards; the elective 3–4-week pre-treatment rule (section 8) does not apply to emergency cardioversion for instability
  • Post-cardioversion: continuous monitoring, repeat 12-lead ECG, treat the underlying cause, and continue anticoagulation per the stroke-risk assessment (section 9)

4 · ECG Diagnosis & Important Differentials

  • Typical ECG features of AF: irregularly irregular ventricular rhythm; absence of consistent, organised P waves (fibrillatory waves may be seen); variable ventricular rate
  • Differentials for an irregular/fast rhythm: atrial flutter (often more organised; can show a regular ventricular response with variable block); SVT; multifocal atrial tachycardia (≥3 distinct P-wave morphologies, usually with underlying lung disease); frequent ectopy; pre-excited AF (AF with WPW)
  • Pre-excited AF / WPW — critical warning: irregular, broad, bizarre-looking, very fast complexes (often >200 bpm) should raise suspicion. Do NOT give AV-nodal blocking drugs (beta-blockers, verapamil, diltiazem, digoxin, adenosine) in suspected pre-excited AF — blocking the AV node can preferentially promote conduction down the accessory pathway and precipitate ventricular fibrillation
  • Management of pre-excited AF: if unstable — immediate synchronised cardioversion as in section 3. If stable — seek urgent senior/cardiology advice; options include IV flecainide (where structural heart disease has been excluded) or synchronised cardioversion; avoid all AV-nodal blocking agents

5 · Investigations in the ED

  • Routine for all patients: 12-lead ECG; continuous cardiac monitoring; blood pressure and oxygen saturation; full blood count; urea & electrolytes/renal function including potassium and magnesium; glucose
  • Indication-dependent: liver function tests (e.g. before starting/adjusting certain drugs); thyroid function tests (to exclude thyrotoxicosis as a cause); troponin (if ischaemia/ACS suspected); chest X-ray (if heart failure, infection, or a pulmonary cause is suspected); venous/arterial blood gas (if unwell, hypoxic, or acid–base disturbance is suspected); further tests directed at any suspected underlying cause (e.g. D-dimer/CTPA if PE suspected, blood cultures if septic)

6 · Rate Control

  • Target: acute ED rate control usually aims for a resting ventricular rate <110 bpm (lenient control) as the initial target for most patients; a stricter target (<80 bpm resting) may be chosen if symptoms persist. This is acute rate control — distinct from long-term/maintenance rate control, which is individualised by cardiology
  • Beta-blockers — first-line in most patients without severe LV dysfunction/decompensated heart failure: IV metoprolol 2.5–5 mg IV over 5 minutes, repeated every 5 minutes as needed to a usual total of 10–15 mg, guided by heart rate/BP · oral bisoprolol 2.5 mg once daily, titrated upward · oral metoprolol 25–50 mg two to three times daily. Onset: IV within minutes, oral within 1–2 hours. Contraindications/cautions: severe asthma/bronchospasm, decompensated heart failure, marked bradycardia/AV block, severe hypotension, pre-excited AF (section 4)
  • Rate-limiting calcium-channel blockers — verapamil/diltiazem: IV verapamil 5–10 mg IV over at least 2 minutes, may repeat 5 mg after 5–10 minutes if needed · oral verapamil 40 mg three times daily or oral diltiazem 60 mg three times daily (modified-release preparations are commonly used for maintenance). UK availability note: an IV diltiazem preparation is not routinely licensed/available in the UK — where an IV non-dihydropyridine calcium-channel blocker is needed, IV verapamil is standard UK ED practice (this differs from some non-UK practice, e.g. in the US, where IV diltiazem is commonly used). Onset: IV within minutes. Contraindications: heart failure with reduced ejection fraction/significant LV systolic dysfunction, hypotension, bradycardia/AV block, concomitant IV beta-blocker use (risk of severe bradycardia/asystole — do not combine IV beta-blocker with IV verapamil/diltiazem), pre-excited AF
  • Digoxin — second-line, particularly for non-paroxysmal AF in sedentary patients or when beta-blockers/calcium-channel blockers are unsuitable (e.g. significant hypotension or decompensated heart failure, since digoxin does not worsen contractility or BP). Loading regimens vary between institutions — a typical approach is IV 500 micrograms diluted in at least 50 mL 0.9% saline or 5% glucose, infused over 1–2 hours, reassessed before any further dose (protocols differ on repeat timing/dose — follow your local protocol/pharmacy advice); an oral loading alternative in less urgent cases is 500 micrograms, then a further 500 micrograms 6 hours later (use a lower, slower loading regimen in renal impairment or age ≥80). Onset: slower than beta-blockers/CCBs (hours). Cautions: renal impairment (reduce dose — accumulation/toxicity risk), hypokalaemia/hypomagnesaemia increase toxicity risk (check and correct first), narrow therapeutic index, numerous drug interactions, pre-excited AF (avoid)
  • Amiodarone — reserved for when beta-blockers/calcium-channel blockers are contraindicated or ineffective, particularly in decompensated heart failure/severe LV dysfunction where other agents are unsafe. Dose: IV 300 mg over 20–60 minutes (ideally via a central line; a large peripheral vein with a dilute solution may be used short-term), followed by 900 mg IV over the next 23–24 hours. Do NOT use amiodarone for routine long-term rate control — reserve it for these acute situations or for rhythm control, given its significant long-term toxicity (thyroid, lung, liver, skin, eyes)
  • Combination therapy: if monotherapy gives inadequate rate control, combining two agents from different classes (e.g. a beta-blocker with digoxin) may be considered — do not combine an IV beta-blocker with IV verapamil/diltiazem, because of the risk of severe bradycardia or asystole
  • Heart failure / LV systolic dysfunction: avoid verapamil/diltiazem; a beta-blocker (if tolerated), digoxin, or amiodarone are preferred
  • COPD/asthma: use beta-blockers with caution in reactive airway disease — a cardioselective agent may be tried cautiously, or a calcium-channel blocker/digoxin used instead in more severe disease
  • Renal impairment and digoxin: reduce the dose and loading regimen, and monitor levels and renal function closely — digoxin accumulates in renal impairment and toxicity risk rises
  • Drug interactions: verapamil and amiodarone both raise digoxin levels; amiodarone potentiates warfarin — check an interaction reference before combining agents

7 · Rhythm Control

  • When to consider rhythm control: persistent symptoms despite rate control; first-episode/short-duration AF with a reversible precipitant; younger patients; or as part of a longer-term strategy in selected patients — the 2024 ESC guidelines now support earlier rhythm control (within 12 months) in selected higher-stroke-risk patients, based on the EAST-AFNET 4 trial
  • Options: electrical cardioversion (section 8); pharmacological cardioversion; antiarrhythmic drugs for maintenance; catheter ablation; referral to cardiology/electrophysiology
  • Catheter ablation: the 2024 ESC/EACTS guidelines now support ablation as a reasonable first-line rhythm-control option (not only after drug failure) for anticoagulation-naive patients with paroxysmal AF, given its superior rhythm-control efficacy over antiarrhythmic drugs in this group — a change from earlier guidance where ablation was typically second-line
  • Pharmacological cardioversion — flecainide: no structural/ischaemic heart disease: IV 2 mg/kg (max 150 mg) over 30 minutes, or an oral loading dose (see pill-in-the-pocket below); contraindicated in structural or ischaemic heart disease, significant LV dysfunction, and Brugada syndrome
  • Pharmacological cardioversion — amiodarone: preferred if structural heart disease/heart failure is present: IV 300 mg over 20–60 minutes, then 900 mg over 23–24 hours, or an oral loading regimen (e.g. 200 mg three times daily for 1 week, then 200 mg twice daily for 1 week, then 200 mg once daily maintenance)
  • Contraindications by context: structural/ischaemic heart disease, heart failure, significant LV dysfunction: avoid flecainide and propafenone (pro-arrhythmic/negative inotropic risk) — use amiodarone instead. Prolonged QT: use amiodarone and other QT-prolonging antiarrhythmics with caution — correct electrolytes first and involve senior/cardiology input
  • 'Pill-in-the-pocket' strategy: a patient-initiated single oral dose of flecainide or propafenone taken at the onset of symptomatic paroxysmal AF, for carefully selected patients. Patient-selection requirements: infrequent, symptomatic, self-terminating episodes; no structural or ischaemic heart disease; no significant LV dysfunction; no Brugada syndrome; the first dose must be given under medical supervision (e.g. in hospital/monitored) to confirm safety and tolerability before the patient self-administers it in the community; typically combined with a pre-taken AV-nodal blocking drug (to prevent 1:1 atrial flutter conduction) unless contraindicated
  • This is an ED safety-awareness point, not an ED-initiated therapy — pill-in-the-pocket is set up and prescribed by cardiology/specialist services, not started de novo in the ED without specialist input

8 · Cardioversion

  • A. Haemodynamically unstable AF: immediate synchronised electrical cardioversion — see section 3. Do not delay for anticoagulation or echocardiography
  • B. Haemodynamically stable AF — electrical vs pharmacological: either may be appropriate; electrical cardioversion has a higher success rate and is preferred when a rapid, reliable return to sinus rhythm is wanted, while pharmacological cardioversion may suit a more gradual, drug-based approach or when sedation for DC cardioversion is best avoided
  • AF duration and cardioversion safety — guidelines differ here, do not conflate them:
  • NICE NG196 (core recommendations last substantively updated 2021): offer rate or rhythm control (including cardioversion) if onset is under 48 hours; if onset is over 48 hours or uncertain, offer rate control and delay cardioversion until the patient has had a minimum of 3 weeks' therapeutic anticoagulation (or use a TOE-guided approach to shorten this — see below)
  • 2024 ESC/EACTS guidelines: lowered the threshold for early cardioversion without prior anticoagulation or TOE to AF of under 24 hours duration (from the previous 48-hour figure), reflecting evidence that such patients are generally low-risk; a 'wait-and-see' approach is also encouraged for recent-onset AF, since a large majority of patients (ESC cites around 69%) spontaneously revert to sinus rhythm within days without any cardioversion at all
  • Practical implication of this divergence: the exact safe cut-off for cardioversion without anticoagulation/TOE (24 vs 48 hours) is genuinely guideline-dependent at the time of writing — follow your local/departmental policy and involve a senior clinician when duration is close to either threshold, rather than assuming either figure applies universally
  • TOE-guided cardioversion: an alternative to a full course of pre-treatment anticoagulation when AF duration is >48h/uncertain (per NICE) — a transoesophageal echocardiogram excludes left atrial/appendage thrombus immediately before cardioversion, allowing earlier cardioversion with only a short period of anticoagulation beforehand. NICE regards TOE-guided and conventional (delayed, anticoagulation-first) cardioversion as equally effective; it requires experienced staff and appropriate facilities
  • Anticoagulation after cardioversion: continue therapeutic anticoagulation for a minimum of 4 weeks after any cardioversion (electrical or pharmacological), regardless of whether sinus rhythm is maintained, because of the risk of atrial stunning and delayed return of effective atrial contraction; continue longer-term if the stroke-risk assessment (section 9) indicates ongoing treatment is needed

9 · Stroke Risk Assessment and Anticoagulation

  • CHA₂DS₂-VASc score (NICE NG196 — still the basis of current NICE guidance): Congestive heart failure/LV dysfunction = 1 · Hypertension = 1 · Age ≥75 = 2 · Diabetes mellitus = 1 · prior Stroke/TIA/systemic embolism = 2 · Vascular disease = 1 · Age 65–74 = 1 · Sex category (female) = 1 — maximum score 9
  • NICE interpretation: offer anticoagulation to all patients (regardless of sex) with a score of 2 or more; consider anticoagulation in men with a score of 1 (weighing bleeding risk); do not offer anticoagulation to patients under 65 with a score of 0 (men) or 1 (women, due only to sex category) — very low stroke risk
  • 2024 ESC/EACTS CHA₂DS₂-VA score — a different, newer system, not identical to CHA₂DS₂-VASc: it removes the sex-category point entirely. Congestive heart failure/LV dysfunction = 1 · Hypertension = 1 · Age ≥75 = 2 · Diabetes mellitus = 1 · prior Stroke/TIA/systemic embolism = 2 · Vascular disease = 1 · Age 65–74 = 1 — maximum score 8
  • Why the change: ESC concluded female sex is a stroke-risk modifier that matters mainly in older women or alongside other risk factors, rather than an independent factor that should always add a point. Under ESC 2024, DOACs are advised for a CHA₂DS₂-VA score of 2 or more, and should be considered for a score of 1, irrespective of sex
  • Do not present these two systems as interchangeable — NICE NG196 (current UK national guidance at the time of writing) is still built around CHA₂DS₂-VASc; CHA₂DS₂-VA is the newer ESC/European approach. Follow whichever your local/departmental policy specifies, and note a woman scored under CHA₂DS₂-VASc may show a numerically different (one point lower) score under CHA₂DS₂-VA for the same risk factors
  • Bleeding-risk assessment: formal tools exist (e.g. ORBIT, HAS-BLED) to identify and address modifiable bleeding-risk factors (uncontrolled hypertension, labile INR, concurrent antiplatelets/NSAIDs, alcohol excess, falls risk)
  • Bleeding risk alone should not automatically exclude anticoagulation — most patients at high bleeding risk are also at high stroke risk, and stroke is generally more disabling than most bleeding events; address modifiable bleeding-risk factors rather than withholding anticoagulation outright, and do not withhold anticoagulation solely because of a patient's age or falls risk
  • Anticoagulation decisions are independent of rhythm status — the need for anticoagulation is driven by the stroke-risk score, not by whether the patient is currently in AF, in sinus rhythm after cardioversion, or has had 'successful' rhythm control
  • After successful cardioversion: continue anticoagulation for a minimum of 4 weeks regardless of stroke-risk score (section 8); continue longer-term if the score indicates it
  • After catheter ablation: continue anticoagulation per the stroke-risk score, generally for at least 2 months post-ablation and long-term if indicated — ablation 'success' does not by itself remove the need for anticoagulation; this is a cardiology-led decision

10 · Anticoagulant Options and Doses

  • Apixaban: standard dose 5 mg twice daily; reduce to 2.5 mg twice daily if 2 or more of: age ≥80 years, body weight ≤60 kg, serum creatinine ≥133 micromol/L. Renal: avoid if creatinine clearance <15 mL/min. Contraindications: active clinically significant bleeding, mechanical heart valves, moderate-to-severe mitral stenosis
  • Rivaroxaban: standard dose 20 mg once daily with food; reduce to 15 mg once daily if creatinine clearance 15–49 mL/min. Renal: avoid if creatinine clearance <15 mL/min
  • Edoxaban: standard dose 60 mg once daily; reduce to 30 mg once daily if creatinine clearance 15–50 mL/min, body weight ≤60 kg, or concomitant potent P-glycoprotein inhibitors (e.g. ciclosporin, dronedarone, erythromycin, ketoconazole). Important: not recommended in patients with high creatinine clearance (>95 mL/min) due to reduced relative efficacy seen in trials — discuss an alternative agent in this group. Renal: avoid if creatinine clearance <15 mL/min
  • Dabigatran: standard dose 150 mg twice daily; reduce to 110 mg twice daily if age ≥80, concomitant verapamil, or increased bleeding risk (e.g. age 75–79, creatinine clearance 30–50 mL/min, gastritis/oesophagitis/reflux disease, other risk factors). Renal: avoid if creatinine clearance <30 mL/min. Reversal: idarucizumab is available for emergency reversal
  • Warfarin: dose individualised and titrated to a target INR 2.0–3.0 (target 2.5); requires regular INR monitoring and has numerous food/drug interactions
  • DOAC general cautions: significant drug interactions (e.g. potent P-glycoprotein/CYP3A4 inhibitors or inducers); confirm renal function before starting and recheck at least annually (more often if renal impairment, elderly, or frail)
  • Valvular AF / mechanical heart valves / moderate-to-severe mitral stenosis: DOACs are not appropriate — these patients require warfarin (DOACs showed harm compared with warfarin in mechanical heart valves in trial data)
  • Pregnancy: DOACs and warfarin are both generally avoided (warfarin is teratogenic; DOACs lack safety data and cross the placenta) — needs specialist obstetric/haematology input, outside the scope of this ED protocol
  • Active major bleeding: withhold anticoagulation, resuscitate, and manage per your local major-bleeding/anticoagulant-reversal protocol

11 · Outpatient / Follow-up Investigations

  • Transthoracic echocardiogram (TTE): indicated for most patients with new AF, to assess LV function, left atrial size, valvular disease, and to exclude an underlying cardiomyopathy — arrange as an outpatient unless there is an indication for it urgently (e.g. suspected heart failure, valvular disease, or haemodynamic instability)
  • Ambulatory ECG monitoring (Holter/event monitor): considered when the diagnosis is uncertain, symptoms don't correlate with documented AF, or to assess rate control/AF burden over time
  • Routine bloods to arrange/complete: thyroid function tests; renal function and electrolytes; diabetes screening (e.g. HbA1c); lipid profile
  • Blood pressure assessment — formal assessment/monitoring for hypertension as an AF risk factor and comorbidity-management target
  • Sleep apnoea assessment where suggested by history (snoring, witnessed apnoeas, daytime somnolence, obesity)
  • Alcohol and lifestyle assessment — alcohol intake, physical activity, weight
  • Urgent vs routine: arrange urgently (before discharge or as expedited follow-up) anything suggesting a serious precipitant or high-risk feature (e.g. echo if heart failure/structural disease suspected, urgent cardiology review if syncope with an abnormal ECG); routine investigations and comorbidity screening can generally proceed through primary care/community cardiology pathways

12 · Management of Precipitants and Comorbidities (AF-CARE)

  • AF-CARE (2024 ESC/EACTS framework) — a structured way to think about every AF patient: Comorbidity and risk-factor management · Avoid stroke and thromboembolism · Reduce symptoms with rate and rhythm control · Evaluation and dynamic reassessment over time
  • Hypertension: treat to target — a major modifiable driver of AF recurrence and stroke risk
  • Heart failure: optimise guideline-directed heart-failure therapy — this also reduces AF burden and recurrence
  • Ischaemic heart disease: manage per standard ACS/ischaemic heart disease pathways; affects the choice of rate/rhythm-control drugs (sections 6–7)
  • Obesity: weight loss reduces AF burden and improves rhythm-control success — a genuine evidence-based intervention, not just general lifestyle advice
  • Diabetes: optimise glycaemic control as part of overall cardiovascular risk reduction
  • Sleep apnoea: treatment (e.g. CPAP) improves AF control and reduces recurrence after cardioversion/ablation where present
  • Thyroid disease: treat thyrotoxicosis/hypothyroidism as an underlying driver
  • Alcohol excess: reducing or stopping alcohol reduces AF recurrence — advise cessation/reduction
  • Smoking: smoking cessation as part of overall cardiovascular risk reduction
  • Physical inactivity: encourage appropriate physical activity as tolerated

13 · Disposition

  • Discharge from ED may be appropriate if: clinically stable; adequate rate control achieved; no acute precipitating condition requiring admission; an appropriate anticoagulation/stroke-risk management plan is in place; appropriate follow-up (GP/cardiology, and outpatient investigations per section 11) is arranged
  • Admission — consider for: haemodynamic instability; acute heart failure; acute coronary syndrome; significant infection/sepsis; significant electrolyte abnormality; syncope or another high-risk presentation; ventricular rate that is difficult to control; failure of initial treatment; significant structural heart disease; any other reason requiring inpatient management or monitoring

14 · Safety Warnings

  • PRE-EXCITED AF/WPW: do NOT give AV-nodal blocking drugs (beta-blockers, verapamil, diltiazem, digoxin, adenosine) — risk of precipitating VF (section 4)
  • HAEMODYNAMIC INSTABILITY: treat with immediate synchronised cardioversion — do not trial rate-control drugs first (section 3)
  • ACUTE HEART FAILURE / SEVERE LV DYSFUNCTION: avoid verapamil/diltiazem; use a beta-blocker cautiously if tolerated, or digoxin, or amiodarone
  • HYPOTENSION: avoid/use extreme caution with IV rate-control drugs that can worsen it (beta-blockers, verapamil/diltiazem) — consider amiodarone or digoxin, and treat any reversible cause of hypotension first
  • BRADYCARDIA/AV BLOCK: avoid combining AV-nodal blocking drugs; use extreme caution with any further rate-control agent
  • LONG QT: avoid amiodarone and other QT-prolonging antiarrhythmics without correcting electrolytes and involving senior/cardiology input first
  • DRUG INTERACTIONS: check before combining rate/rhythm-control drugs or starting/adjusting anticoagulants — amiodarone and verapamil both raise digoxin levels; amiodarone potentiates warfarin
  • RENAL IMPAIRMENT: adjust digoxin and DOAC doses as above; recheck renal function regularly on any of these drugs
  • DOAC DOSING ERRORS: apply the correct dose-reduction criteria for the specific DOAC (section 10) — an incorrect standard-dose prescription in a patient who should be dose-reduced (or vice versa) is a recognised, preventable source of harm
  • MECHANICAL HEART VALVES / MODERATE-SEVERE MITRAL STENOSIS: DOACs are not appropriate — use warfarin
← Back to all protocols